Skip to content

Study · Randomized controlled trial · 2020

4 results

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.

Alvarez XA, Alvarez I, Martinez A, Romero I, Benito C, Suarez I, Mourente S, Fantini M, Figueroa J, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H

The international journal of neuropsychopharmacology1 Dec 2020Cited by 5 (Europe PMC)

PMID32640027 (opens in a new tab)PMCIDPMC7710915 (opens in a new tab)DOI10.1093/ijnp/pyaa046 (opens in a new tab)PepBankPUB-32640027
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In patients with advanced Alzheimer's disease, adding Cerebrolysin to donepezil reduced elevated serum VEGF compared with donepezil alone.

    In plain wordsIn patients with advanced Alzheimer's disease, adding Cerebrolysin reduced serum VEGF compared with donepezil alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSerum VEGF
    Study

    n: not reported in source

    Comparator
    Donepezil alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels.
    1 context sentence
    Summary · context
    This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with advanced Alzheimer's disease, adding Cerebrolysin to donepezil improved functioning compared with donepezil alone.

    In plain wordsIn patients with advanced Alzheimer's disease, adding Cerebrolysin improved functioning compared with donepezil alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctioning
    Study

    n: not reported in source

    Comparator
    Donepezil alone
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels.
    1 context sentence
    Summary · context
    This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with advanced Alzheimer's disease, adding Cerebrolysin to donepezil improved cognition compared with donepezil alone.

    In plain wordsIn patients with advanced Alzheimer's disease, adding Cerebrolysin improved cognition compared with donepezil alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognition
    Study

    n: not reported in source

    Comparator
    Donepezil alone
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels.
    1 context sentence
    Summary · context
    This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial.
  4. 04HumanRandomized controlled trialOther

    In patients with advanced Alzheimer's disease, higher baseline VEGF was linked to greater differences between Cerebrolysin plus donepezil and donepezil alone.

    In plain wordsIn advanced Alzheimer's disease, higher baseline VEGF was linked to greater differences between Cerebrolysin plus donepezil and donepezil alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBaseline VEGF and treatment response
    Study

    n: not reported in source

    Comparator
    Donepezil alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels.
    1 context sentence
    Summary · context
    This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.